Neurology India
menu-bar5 Open access journal indexed with Index Medicus
  Users online: 7430  
 Home | Login 
About Editorial board Articlesmenu-bullet NSI Publicationsmenu-bullet Search Instructions Online Submission Subscribe Videos Etcetera Contact
  Navigate Here 
 »   Next article
 »   Previous article
 »   Table of Contents

 Resource Links
 »   Similar in PUBMED
 »  Search Pubmed for
 »  Search in Google Scholar for
 »Related articles
 »   Citation Manager
 »   Access Statistics
 »   Reader Comments
 »   Email Alert *
 »   Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded158    
    Comments [Add]    
    Cited by others 12    

Recommend this journal


Year : 2011  |  Volume : 59  |  Issue : 4  |  Page : 555--557

Induced pluripotent stem cells and promises of neuroregenerative medicine

1 University of Miami Miller School of Medicine, Miami, Florida, USA
2 Weill Cornell Medical College at Cornell University, New York, USA

Correspondence Address:
Ashok Verma
Clinical Research Building, 1120 NW 14 Street, Suite 1317, Miami, FL 33136
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/0028-3886.84337

Rights and Permissions

First created in 2006 from adult somatic cells by a simple molecular genetic trick, induced pluripotent stem cells (iPS) system is the latest platform in stem cell research. Induced pluripotent stem cells are produced by nuclear reprogramming technology and they resemble embryonic stem cells (ES) in key elements; they possess the potentiality to differentiate into any type of cell in the body. More importantly, the iPS platform has distinct advantage over ES system in the sense that iPS-derived cells are autologous and therefore the iPS-derived transplantation does not require immunosuppressive therapy. In addition, iPS research obviates the political and ethical quandary associated with embryo destruction and ES research. This remarkable discovery of cellular plasticity has important medical implications. This brief review summarizes currently available stem cell platforms, with emphasis on cellular reprogramming and iPS technology and its application in disease modeling and cell replacement therapy in neurodegenerative diseases.


Print this article     Email this article

Online since 20th March '04
Published by Wolters Kluwer - Medknow